Accurate kinetics and affinity data is essential for predicting the efficacy of novel therapeutics and for making quick decisions about candidates. However, analysis methods that require labelling can cause steric interference and influence data outcomes.
Surface plasmon resonance (SPR) immunoassays are the gold standard technique for real-time antibody–antigen binding analyses in target-based drug discovery. When paired with the latest technology, SPR methods can provide ready-to-go interaction analysis and highly reproducible data.
This compendium of infographics explores how streamlining affinity and kinetics analyses can accelerate drug discovery workflows.
Gain access to this compendium to discover:
- Label-free approaches to gaining robust results from “difficult” samples
- Predefined software methods that are intuitive and easy to use
- The role of SPR in transforming drug discovery research
Surface plasmon resonance (SPR): Three decades of SPR supporting target-based drug discovery cytiva.com Cytiva and the Drop Logo are trademarks of Global Life Sciences IP Holdco LLC or an affiliate. Biacore is a trademark of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva. Humira is a trademark of Abbvie Biotechnology Ltd. All other third-party trademarks are the property of their respective owners. For local office contact information, visit cytiva.com/contact. ©2020 Cytiva CY16061-30Sep20-PO SPR was first used successfully in the characterization of the antibody-based drug, Humira™, in the early 1990s. Today, SPR is the standard for real-time detection of antibody-antigen binding and kinetics in target–based drug discovery. • 1990: Abbott was the first to buy Biacore™ SPR system. • Biopharma industry adopts SPR technology to determine antibody-antigen affinity, kinetics, and epitope binning. • Phage display provides fully human antibody libraries. • 1997: FDA approves first humanized mAb developed using SPR for the prevention of transplant rejection — anti-IL-2 receptor. • Unknown molecule binding to target of interest could be identified by connecting SPR to mass spectrometry. 1990–1999 • 2003: Alefacept, the first biologics for skin disorder, used Biacore™ system for drug release to ensure patient safety and drug efficacy. • 2008: About 50% of new medicines released use a target-based discovery strategy. • The sensitivity and throughput of SPR enables screening of large libraries of fragments or compounds. SPR makes binding analysis of challenging targets like G protein-coupled receptors (GPCRs) possible. 2000–2010 • First pharmaceutical developed through fragment-based drug discovery is launched. • ~ 25% of the top 100 selling drugs-target are GPCRs. • 2018: eight of the top 10 bestselling drugs worldwide are biologics. • SPR technology included in Pharmacopeia for United States, Europe, and Japan
